Michael Buckstein, MD, PhD
img_Michael Buckstein
ASSOCIATE PROFESSOR | Radiation Oncology
Are you a patient?
Radiation Oncology
Research Topics
Identifying Genetic Predictors for Radiation Treatment Related Toxicity

Dr, Buckstein is involved in mutliple projects using Genome-Wide Association Studies (GWAS) to identify individual genetic differences that might predict for the development of radiation toxicity. This will ultimately allow physicians to personalize therapy to each individual, potentially minimizing toxicity and optimizing therpeutic outcomes.

Use of Stereotactic Body Radiation Therapy and Hepatocellular Carcinomas
Dr. Buckstein is the principal investigator on a study using combination trans-arterial chemo embolization (TACE) with stereotactic body radiation therapy (SBRT) as a treatment paradigm for treating large hepatocellular carcinomas.  In addition, he is actively working to safely integrate SBRT into treatment paradigms for HCC.
Outcomes Based Research for Gastrointestinal Malignancies
Using a variety of tools institutional and national based databases, Dr. Buckstein is involved with research attempting to identify treatment related predictors for outcomes and development of treatment related toxicities. He has a particular focus on understanding outcomes with patients who have Inflammatory Bowel Disease who develop a malignancy. 

PhD, University of Pennsylvania School of Medicine

MD, University of Pennsylvania School of Medicine

Residency, Internal Medicine, Long Island Jewish Medical Center

Residency, Radiation Oncology, Mount Sinai Hospital


Radiation Oncology


Roentgen Resident Research Award

Radiological Society of North America


Best of ASTRO Award

New York Roentgen Society


John G. Clark Prize

University of Pennsylvania School of Medicine


Medical Scientist Training Program Fellowship

National Institutes of Health

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Dr. Buckstein has not yet completed reporting of Industry relationships.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.